Loading...

TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Capital Structure Changes 8-K Filing

TV P

TV

TEVA PHARMACEUTICAL INDUSTRIES LTD

(TEVA)

2025 8-K

Credit Agreement Update

Financial Results Update

Financial Statements

Debt Restructuring

Equity Offerings

Financial Statements

Financial Results

Board Appointment

Q3 Financial Results

Financial Results Announcement

Agreement with Israeli Tax ...

Annual Meeting Voting Results

Departure and Appointment o...

Financial Results Announcement

Change in Reporting Segments

Financial Results Announcement

Financial Results Announcement

Collaboration with Sanofi

Departure and Appointment

Entry into a Material Defin...

Appointment of Director

Financial Results Announcement

Annual Meeting Voting Results

Settlement Agreement for Op...

Resignation of Director

Financial Results

External Links:

Teva Pharmaceutical Industries Ltd extended the maturity date of its revolving credit agreement from April 29, 2027, to April 29, 2028, with a maximum leverage ratio set at 4.25x effective Q4 2025, as reported on December 10, 2025.

AI Assistant

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.